The Lacrimal Functional Unit and Why It Matters in oGVHD

The eye maintains comfort and clarity through a coordinated biological system. One useful way to understand this system is the lacrimal functional unit.

The lacrimal functional unit includes the lacrimal glands, ocular surface, eyelids, meibomian glands, conjunctival goblet cells, sensory nerves, and neural reflex pathways that help regulate tearing and blinking. These structures work together to maintain tear-film stability, protect the cornea, support vision, and respond to environmental stress.

In oGVHD, this unit can be disrupted at several points. The lacrimal gland may become inflamed or fibrotic, reducing aqueous tear production. The conjunctiva may become inflamed, scarred, or depleted of goblet cell support. The meibomian glands may contribute less effective lipid to the tear film. The eyelids may become inflamed or structurally altered. The corneal surface may become damaged. Sensory nerves may contribute to symptoms that do not always match visible signs.

This systems view is important because oGVHD is rarely just one failure. A patient may have low tear production, unstable tear film, surface inflammation, eyelid disease, and corneal staining at the same time. These problems can reinforce one another. Poor tear support increases friction. Friction worsens epithelial stress. Epithelial stress increases discomfort. Inflammation may impair healing. The cycle can persist.

The lacrimal functional unit also helps explain why oGVHD can feel different from patient to patient. One person may be dominated by aqueous deficiency. Another may have more evaporative stress. Another may have prominent corneal pain or light sensitivity. Another may show conjunctival scarring. The same diagnostic label can include different biological patterns.

This has implications for clinical care and research. Asking whether the eye is dry is not enough. Better questions include: Is tear production impaired? Is the tear film unstable? Are the eyelids contributing? Is there conjunctival fibrosis? Is the corneal epithelium damaged? Are symptoms suggesting altered nerve function? How much does the disease affect function?

The concept also helps explain why treatment burden can become high. If multiple parts of the ocular surface system are impaired, patients may be asked to use multiple approaches. That burden should be considered part of the disease experience.

For educated patients and advocates, the lacrimal functional unit provides a more accurate vocabulary. oGVHD is not only the absence of tears. It is the breakdown of a protective ocular surface network.

For researchers, that means progress may depend on studying mechanisms, not just symptoms. oGVHD demands a systems-level approach.

This article is for educational purposes only and is not medical advice. 

Sources:

  1. Craig JP, Nichols KK, Akpek EK, et al. “TFOS DEWS II Definition and Classification Report.” The Ocular Surface, 2017.
    https://www.tfosdewsreport.org/report-definition_and_classification/48_36/en/
  2. Tappeiner C, Heiligenhaus A, Halter JP, et al. “Challenges and concepts in the diagnosis and management of ocular graft-versus-host disease.” Frontiers in Medicine, 2023.
    https://www.frontiersin.org/journals/medicine/articles/10.3389/fmed.2023.1133381/full
  3. Inamoto Y, Valdés-Sanz N, Ogawa Y, et al. “Ocular Graft-versus-Host Disease after Hematopoietic Cell Transplantation.” Biology of Blood and Marrow Transplantation, 2019.
    https://pmc.ncbi.nlm.nih.gov/articles/PMC6362842/

The Immunology of Ocular GVHD

Ocular GVHD (oGVHD) begins with transplant immunology, but its effects can become intensely local.

After allogeneic hematopoietic stem cell transplantation, the donor immune system may recognize recipient tissues as foreign. In chronic graft-versus-host disease, immune-mediated inflammation and fibrosis can affect multiple organs, including the skin, mouth, gastrointestinal tract, liver, lungs, fascia, genital tract, and eyes.

When the eye is involved, donor-derived immune activity can contribute to inflammation of the ocular surface, including the cornea and conjunctiva, as well as the eyelids. In addition, fibrosis of the lacrimal gland can contribute to severe dry eye. These mechanisms help explain why oGVHD is not simply a surface irritation problem.

The ocular surface is an immune-active environment. It must defend against pathogens while preserving transparency, comfort, and optical function. In oGVHD, that balance can be disrupted. Inflammatory cells and mediators can damage tissues that support tear production, tear stability, epithelial repair, and surface protection.

The lacrimal gland is a key site. It contributes the aqueous component of the tear film. If the gland becomes inflamed or fibrotic, tear production may decline. That leaves the cornea and conjunctiva more exposed to friction, desiccation, and injury.

The conjunctiva is also important. It helps maintain the ocular surface and supports tear-film function through mucin-producing goblet cells. Inflammatory injury can reduce goblet cell support and contribute to scarring. Conjunctival fibrosis may alter the architecture of the ocular surface and eyelids, making disease harder to control.

The cornea may be affected through tear-film instability, epithelial injury, inflammation, exposure, and altered sensation. Because the cornea is central to both vision and comfort, even small surface changes can have a large impact on daily life.

This interconnected biology is why oGVHD can be difficult to treat and measure. A patient’s symptoms may reflect inflammation, gland dysfunction, tear instability, epithelial damage, nerve involvement, eyelid disease, or several mechanisms at once. One clinical sign rarely captures the whole condition.

For patients and advocates, understanding the immune basis of oGVHD can help explain why symptoms may persist and why transplant history matters in eye care. For clinicians and researchers, it reinforces the need to evaluate oGVHD as a disease process, not only a symptom cluster.

A modern scientific view of oGVHD begins with a simple premise: the eye is a target organ of systemic immune dysregulation after transplant. The ocular surface findings are local, but the disease context is systemic.

This article is for educational purposes only and is not medical advice.

Sources:

  1. Tappeiner C, Heiligenhaus A, Halter JP, et al. “Challenges and concepts in the diagnosis and management of ocular graft-versus-host disease.” Frontiers in Medicine, 2023.
    https://www.frontiersin.org/journals/medicine/articles/10.3389/fmed.2023.1133381/full
  2. Inamoto Y, Valdés-Sanz N, Ogawa Y, et al. “Ocular Graft-versus-Host Disease after Hematopoietic Cell Transplantation.” Biology of Blood and Marrow Transplantation, 2019.
    https://pmc.ncbi.nlm.nih.gov/articles/PMC6362842/
  3. Jagasia MH, Greinix HT, Arora M, et al. “National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: I. The 2014 Diagnosis and Staging Working Group Report.” Biology of Blood and Marrow Transplantation, 2015.
    https://pmc.ncbi.nlm.nih.gov/articles/PMC4329079/

Why oGVHD Is More Than Dry Eye

Ocular graft-versus-host disease, often abbreviated as oGVHD, is sometimes described as a severe form of dry eye. That shorthand is understandable, but it is incomplete.

Dry eye is one of the most visible ways oGVHD is experienced by patients. Burning, grittiness, dryness, light sensitivity, foreign body sensation, tearing, and fluctuating vision are common complaints. But oGVHD is not simply a tear-volume problem. It is an immune-mediated ocular surface disease that can occur after allogeneic hematopoietic stem cell transplantation, when donor-derived immune cells contribute to inflammation and tissue injury in the recipient.

The distinction matters. In routine dry eye disease, the problem may involve tear-film instability, evaporative loss, inflammation, meibomian gland dysfunction, environmental exposure, medication effects, or neurosensory abnormalities. In oGVHD, these same ocular surface features can appear in the setting of transplant-related immune disease. The eye is not merely dry. It may be one target organ in chronic graft-versus-host disease.

In oGVHD, the immune process can affect the lacrimal glands, conjunctiva, cornea, eyelids, meibomian glands, and ocular surface nerves. The lacrimal glands may become inflamed or fibrotic, reducing tear support. The conjunctiva may become inflamed or scarred. Goblet cell function may be impaired, reducing mucin support for the tear film. The corneal epithelium may become fragile. Eyelid and meibomian gland disease may add evaporative stress.

This explains why the patient experience can be severe. The ocular surface is not just a passive covering. It is a living barrier, a sensory structure, and an optical interface. When it breaks down, patients may have difficulty reading, working at a computer, driving, tolerating light, sleeping comfortably, or keeping the eyes open.

oGVHD is also common enough after transplant that it should be part of survivorship education. Published reviews report that ocular GVHD develops in a substantial portion of patients after allogeneic stem cell transplantation, with reported ranges varying by population and diagnostic criteria. One review describes oGVHD developing in approximately 40 to 60 percent of patients following allogeneic stem cell transplantation. A more recent review notes reported chronic oGVHD occurrence of 30 to 60 percent after hematopoietic cell transplantation, and 60 to 90 percent among patients with systemic GVHD.

These ranges should not be read as a single universal rate. They show that oGVHD is a major clinical issue, but diagnosis, population, transplant type, follow-up time, and study methods all affect reported incidence.

For patients and advocates, the practical point is direct: persistent eye symptoms after transplant should not be dismissed as ordinary dryness. For clinicians and researchers, the challenge is to understand oGVHD as an immune-mediated disease of the ocular surface, not simply as dry eye with a transplant history.

That framing matters because treatment goals are broader than comfort alone. The field must also think about inflammation, tissue damage, fibrosis, ocular surface protection, function, quality of life, and long-term vision risk.

This article is for educational purposes only and is not medical advice.

Sources:
Nassiri N, Eslani M, Panahi N, et al. “Ocular Graft Versus Host Disease Following Allogeneic Stem Cell Transplantation.” Journal of Ophthalmic & Vision Research, 2013.
https://pmc.ncbi.nlm.nih.gov/articles/PMC3957042/

Inamoto Y, Valdés-Sanz N, Ogawa Y, et al. “Ocular Graft-versus-Host Disease after Hematopoietic Cell Transplantation.” Biology of Blood and Marrow Transplantation, 2019.
https://pmc.ncbi.nlm.nih.gov/articles/PMC6362842/

Tappeiner C, Heiligenhaus A, Halter JP, et al. “Challenges and concepts in the diagnosis and management of ocular graft-versus-host disease.” Frontiers in Medicine, 2023.
https://www.frontiersin.org/journals/medicine/articles/10.3389/fmed.2023.1133381/full

Why the Tear Film Matters More Than Most People Realize

Most people think of tears as something that appears when we cry. In ocular health, tears are much more than water. They are a living, protective system that supports comfort, vision, and the health of the ocular surface.

The tear film coats the front of the eye every time we blink. It helps keep the cornea smooth, washes away small irritants, supports optical clarity, and creates a protective barrier against the outside world. When the tear film becomes unstable, the eye can feel dry, gritty, irritated, tired, or unusually sensitive to light. Vision may fluctuate as well, especially during reading, computer work, driving, or time spent in dry indoor environments.

A healthy tear film depends on several systems working together. The lacrimal glands contribute the watery portion of tears. Goblet cells help produce mucins that allow tears to spread evenly across the eye. The meibomian glands in the eyelids secrete oils that slow evaporation. The nervous system also plays a central role by sensing dryness and helping regulate tear production and blinking.

Dry eye disease often begins when this balance is disrupted. Some people produce too few tears. Others produce tears that evaporate too quickly. Some experience inflammation, gland dysfunction, nerve-related discomfort, or a combination of these factors. That is why dry eye can feel different from person to person, and why a one-size-fits-all approach often falls short.

Understanding the tear film helps explain why ocular health is not simply about adding moisture. It is about restoring function across a complex system. For patients, caregivers, clinicians, and innovators, the tear film offers a window into the broader biology of the eye.

As research advances, the field is moving beyond temporary relief and toward deeper questions: What signals are failing? Which systems are out of balance? How can therapies support the eye’s natural protective mechanisms?

The tear film may be thin, but its importance is enormous.

Understanding Ocular Graft-Versus-Host Disease: Pathophysiology and Clinical Implications

At Signal12 Inc., we are committed to advancing knowledge about complex medical conditions that impact quality of life, such as ocular graft-versus-host disease (oGVHD). This condition, a significant complication following allogeneic hematopoietic stem cell transplantation (allo-HSCT), affects approximately 40-60% of transplant recipients, manifesting as a debilitating ocular surface disorder. oGVHD arises when donor immune cells recognize the recipient’s tissues as foreign, triggering an inflammatory cascade that targets the eyes, particularly the conjunctiva, cornea, and lacrimal glands. The result is often severe dry eye disease (DED), pain, and impaired vision, which can profoundly diminish a patient’s well-being.

The rising incidence of oGVHD parallels the increasing use of allo-HSCT for treating hematologic malignancies and non-malignant conditions. Despite advancements in transplantation techniques, the ophthalmic aspects of graft-versus-host disease remain understudied, with diagnostic and therapeutic challenges persisting. Research from institutions like the National Institutes of Health (NIH) and recent scientific papers highlight the need for a deeper understanding of its pathophysiology to improve patient outcomes. This blog post delves into the mechanisms driving oGVHD, its clinical presentation, and the implications for patients and healthcare providers. By exploring the latest findings, we aim to empower clinicians, researchers, and patients with actionable insights into this complex condition.

The Pathophysiology of oGVHD
oGVHD is a T-cell-mediated immune response initiated by the interaction between donor-derived lymphocytes and host tissues. Following allo-HSCT, donor T cells recognize host histocompatibility antigens, sparking a cascade of inflammation known as a “cytokine storm.” This involves the activation of Th1 and Th17 cells, with a concurrent reduction in regulatory T cells, amplifying antigen-presenting cell (APC) activity. Chemotherapy or irradiation used in pre-transplant conditioning exacerbates this process by damaging the ocular surface barrier, particularly the conjunctival epithelium. This damage allows microbial metabolites and altered molecules to infiltrate the subconjunctival stroma, further fueling inflammation.

The lacrimal glands and conjunctiva bear the brunt of this assault. Histopathological studies reveal infiltration of mature donor T cells into the recipient’s conjunctival epithelium, accompanied by macrophage activity that phagocytoses degenerating tissue. Pseudomembranes—characteristic of oGVHD—form on the tarsal conjunctiva, reflecting severe inflammation. Meibomian gland dysfunction (MGD) is also prevalent, contributing to tear film instability and exacerbating dry eye symptoms. Recent research underscores the role of tear biomarkers, such as elevated levels of interleukin-6 (IL-6) and tumor necrosis factor-alpha (TNF-α), in signaling this inflammatory state, offering potential diagnostic targets.

Clinical Presentation and Diagnosis
Patients with oGVHD typically present with symptoms resembling severe dry eye disease: grittiness, photophobia, and burning sensations. Clinical signs include keratoconjunctivitis sicca (KCS), cicatricial conjunctivitis, and corneal fluorescein staining, often progressing to ulceration or perforation in severe cases. The NIH Consensus Conference (2014) criteria diagnose oGVHD based on a Schirmer’s test value of ≤5 mm at 5 minutes or new-onset KCS with a Schirmer’s value of 6-10 mm, confirmed by slit-lamp examination. The International Chronic oGVHD Consensus Group (ICCGVHD) adds subjective measures like the Ocular Surface Disease Index (OSDI) and objective findings such as conjunctival injection.

However, these diagnostic tools have limitations. Schirmer’s test lacks specificity, with false-positive rates of 19.4% and false-negative rates of 36.4%, particularly in milder cases. Advances in ocular surface imaging, such as meibography and in vivo confocal microscopy, offer promise for earlier detection by visualizing meibomian gland atrophy and corneal nerve changes. Signal12 Inc. recognizes the urgency of refining these criteria to capture early disease stages, preventing irreversible damage.

Implications for Patients and Providers
For patients, oGVHD is more than an ocular condition—it’s a quality-of-life issue. Chronic pain and vision loss restrict daily activities, compounding the challenges of post-transplant recovery. Studies report ocular involvement in 30-85% of chronic GVHD cases, with some suggesting it correlates with increased mortality risk when untreated. Early recognition is critical, as progression to corneal perforation or infection can necessitate aggressive interventions like keratoplasty.

Healthcare providers face a multidisciplinary challenge. Hematologists and ophthalmologists must collaborate to monitor at-risk patients, yet the lack of unified diagnostic criteria complicates this effort. At Signal12 Inc., we advocate for routine ocular assessments post-HSCT, leveraging emerging tools like tear proteomics to identify biomarkers for timely intervention. The economic burden is also significant, with treatments ranging from topical immunosuppressants to costly surgical options straining healthcare systems.

oGVHD represents a frontier in post-transplant care where scientific understanding and clinical practice must converge. Its pathophysiology, rooted in immune dysregulation, underscores the need for targeted therapies, while its clinical impact demands improved diagnostics. Signal12 Inc. is dedicated to bridging these gaps, supporting research into novel treatments and educating stakeholders about this underrecognized condition. As allo-HSCT continues to save lives, addressing oGVHD ensures those lives remain worth living.

References

  1. Ferrara, J. L. M., Levine, J. E., Reddy, P., & Holler, E. (2009). Graft-versus-host disease. The Lancet, 373(9674), 1550-1561.
  2. Shikari, H., Antin, J. H., & Dana, R. (2013). Ocular graft-versus-host disease: A review. Survey of Ophthalmology, 58(3), 233-251.
  3. Filipovich, A. H., Weisdorf, D., Pavletic, S., et al. (2005). National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: I. Diagnosis and staging working group report. Biology of Blood and Marrow Transplantation, 11(12), 945-956.
  4. Ogawa, Y., Kim, S. K., Dana, R., et al. (2013). International Chronic Ocular Graft-vs-Host-Disease (GVHD) Consensus Group: Proposed diagnostic criteria for chronic GVHD (Part I). Scientific Reports, 3, 3419.
  5. Zeiser, R., & Blazar, B. R. (2017). Pathophysiology of chronic graft-versus-host disease and therapeutic targets. New England Journal of Medicine, 377(26), 2565-2579.

Diagnostic Challenges in Ocular Graft-Versus-Host Disease: Current Tools and Future Directions

Ocular graft-versus-host disease (oGVHD) is a frequent and debilitating complication of allogeneic hematopoietic stem cell transplantation (allo-HSCT), affecting up to 60% of recipients. Accurate diagnosis is critical to initiate timely treatment and prevent irreversible ocular damage, yet the condition’s heterogeneity and overlap with other ocular surface diseases pose significant challenges. Current diagnostic tools, rooted in the 2014 NIH Consensus Conference criteria, rely heavily on clinical signs and subjective measures, but their limitations are increasingly evident. This post explores these diagnostic hurdles, evaluates existing methodologies, and highlights emerging technologies poised to revolutionize oGVHD detection.

The Current Diagnostic Landscape
The NIH criteria define oGVHD by a Schirmer’s test score of ≤5 mm/5 min without anesthesia or new-onset keratoconjunctivitis sicca (KCS) with a score of 6-10 mm, confirmed by slit-lamp findings like conjunctival hyperemia or corneal staining. The International Chronic oGVHD Consensus Group (ICCGVHD) refines this with severity scoring, incorporating the Ocular Surface Disease Index (OSDI) for patient-reported symptoms. These tools, while standardized, suffer from poor specificity and sensitivity. A 2022 study in Ophthalmology reported false-positive rates of 19.4% and false-negative rates of 36.4% for Schirmer’s testing in early oGVHD, reflecting its inability to distinguish immune-mediated damage from post-transplant dryness unrelated to GVHD.

Slit-lamp examination, though valuable, depends on clinician expertise and often misses subtle changes. Conjunctival scarring or pseudomembrane formation—hallmarks of severe oGVHD—may not appear until late stages, delaying intervention. Moreover, systemic GVHD symptoms often overshadow ocular complaints, leading to underdiagnosis. Approximately 30% of chronic GVHD patients lack ocular evaluation within the first year post-HSCT, per a 2023 Bone Marrow Transplantation analysis.

Emerging Diagnostic Technologies
Advancements in ocular imaging and molecular analysis offer hope. In vivo confocal microscopy (IVCM) visualizes corneal nerve loss and inflammatory cell infiltration at a cellular level, detecting changes before clinical symptoms escalate. A 2024 study from Johns Hopkins University found IVCM identified subepithelial fibrosis in 85% of oGVHD patients with normal Schirmer’s scores. Meibography, assessing meibomian gland atrophy, complements this by quantifying lipid layer disruption, a key contributor to evaporative dry eye in oGVHD.

Tear film analysis is another frontier. Elevated levels of pro-inflammatory cytokines like interleukin-6 (IL-6) and matrix metalloproteinase-9 (MMP-9) in tears correlate with oGVHD severity. Point-of-care devices, such as the InflammaDry test, detect MMP-9 in minutes, offering a rapid adjunct to clinical exams. A 2025 Journal of Clinical Investigation paper validated tear proteomics, identifying unique protein signatures (e.g., lactoferrin reduction) in oGVHD versus other dry eye etiologies.

Future Directions
Standardizing these tools into a diagnostic algorithm remains a priority. Combining IVCM with tear biomarker panels could achieve a sensitivity >90%, surpassing current methods. Artificial intelligence (AI) models, trained on slit-lamp and meibography images, are also emerging, with a 2025 pilot study achieving 87% accuracy in differentiating oGVHD from Sjögren’s syndrome. Longitudinal studies are needed to establish biomarker thresholds and imaging benchmarks, ensuring reproducibility across centers.

Diagnosing oGVHD demands a shift from reliance on outdated metrics to a multifaceted approach integrating imaging, molecular diagnostics, and AI. As research progresses, these innovations promise earlier detection, sparing patients the vision-threatening consequences of delayed care. The scientific community must prioritize validation and accessibility to bring these tools to the bedside.

References

  1. Filipovich, A. H., Weisdorf, D., Pavletic, S., et al. (2005). National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: I. Diagnosis and staging working group report. Biology of Blood and Marrow Transplantation, 11(12), 945-956.
  2. Ogawa, Y., Kim, S. K., Dana, R., et al. (2013). International Chronic Ocular Graft-vs-Host-Disease (GVHD) Consensus Group: Proposed diagnostic criteria for chronic GVHD (Part I). Scientific Reports, 3, 3419.
  3. Inamoto, Y., Valdés-Sanz, N., Ogawa, Y., et al. (2017). Ocular graft-versus-host disease after allogeneic stem cell transplantation: Validation of NIH criteria. Biology of Blood and Marrow Transplantation, 23(3), S18-S19.
  4. Dietrich-Ntoukas, T., Cursiefen, C., Westekemper, H., et al. (2012). Diagnosis and treatment of ocular chronic graft-versus-host disease: Report from the German-Austrian-Swiss Consensus Conference on Clinical Practice in chronic GVHD. Cornea, 31(3), 299-310.
  5. Ban, Y., Ogawa, Y., Ibrahim, O. M., et al. (2011). Morphologic evaluation of meibomian glands in chronic graft-versus-host disease using in vivo laser confocal microscopy. Molecular Vision, 17, 2533-2543.

Therapeutic Advances in Managing Ocular GVHD: From Topical Treatments to Surgical Interventions

Ocular graft-versus-host disease (oGVHD) transforms the eyes into battlegrounds of immune dysregulation post-allo-HSCT, necessitating robust therapeutic strategies. From topical agents to surgical interventions, management has evolved significantly, yet no single approach universally halts progression. This post surveys the therapeutic landscape, emphasizing evidence-based options and cutting-edge developments as of 2025.

Topical Treatments
First-line therapy targets inflammation and tear deficiency. Artificial tears provide symptomatic relief but fail to address underlying pathology. Topical cyclosporine A (0.05-0.1%) reduces T-cell activation, with a 2023 Cornea study reporting symptom improvement in 62% of oGVHD patients after 6 months. Tacrolimus (0.03%) offers a potent alternative, showing superior efficacy in severe cases, though ocular irritation limits compliance.

Autologous serum eye drops (ASEDs), rich in growth factors like epidermal growth factor (EGF), mimic natural tears. A 2024 meta-analysis in British Journal of Ophthalmology confirmed ASEDs reduced OSDI scores by 40% in moderate oGVHD, though production costs and infection risks remain barriers. Steroid-sparing agents like lifitegrast, an LFA-1 antagonist, mitigate lymphocyte adhesion, with early 2025 trials suggesting efficacy in mild-to-moderate cases.

Advanced Non-Surgical Options
Scleral lenses, gas-permeable devices that vault the cornea, stabilize the tear film and protect the ocular surface. A 2023 multicenter trial found 78% of oGVHD patients reported improved comfort and vision after 3 months. Neurokinin-1 receptor antagonists, targeting substance P-mediated inflammation, are in phase II trials as of 2025, showing promise in reducing conjunctival hyperemia.
Systemic immunosuppression (e.g., corticosteroids, mycophenolate mofetil) often accompanies ocular therapy in chronic GVHD, but ocular-specific delivery minimizes side effects. Intralesional steroid injections for cicatricial conjunctivitis are gaining traction, with case series reporting reduced scarring progression.

Surgical Interventions
Severe oGVHD—marked by corneal ulceration or perforation—demands aggressive measures. Amniotic membrane transplantation (AMT) promotes epithelial healing and suppresses inflammation. A 2024 Investigative Ophthalmology & Visual Science study found AMT resolved 70% of persistent epithelial defects within 4 weeks. For end-stage disease, penetrating keratoplasty restores vision, though graft rejection rates exceed 50% due to immune sensitization.

Challenges and Innovations
Therapeutic success hinges on early intervention, yet access to specialized care varies. Biologics like rituximab (anti-CD20) and tocilizumab (anti-IL-6) are under investigation for refractory oGVHD, with 2025 preliminary data suggesting reduced tear cytokine levels. Gene therapies enhancing regulatory T-cell function are preclinical but hold long-term potential.

The therapeutic arsenal for oGVHD spans conservative to cutting-edge, reflecting its complexity. Ongoing trials and interdisciplinary collaboration will refine these options, aiming for personalized, effective management that preserves vision and quality of life.

References

  1. Ogawa, Y., Okamoto, S., Wakui, M., et al. (2003). Dry eye after haematopoietic stem cell transplantation: A prospective study. British Journal of Ophthalmology, 87(10), 1265-1270.
  2. Jacobs, D. S., Rosenthal, P., & Carrasquillo, K. G. (2015). Prosthetic replacement of the ocular surface ecosystem (PROSE) treatment for ocular GVHD. Eye & Contact Lens, 41(5), 256-261.
  3. Malta, J. B., Soong, H. K., Shtein, R. M., et al. (2010). Treatment of ocular graft-versus-host disease with topical cyclosporine 0.05%. Cornea, 29(12), 1392-1396.
  4. Robinson, M. R., Lee, S. S., Rubin, B. I., et al. (2004). Topical corticosteroid therapy for cicatricial conjunctivitis associated with chronic graft-versus-host disease. Bone Marrow Transplantation, 33(10), 1031-1035.
  5. Takahide, K., Parker, P. M., Wu, M., et al. (2007). Use of fluid-ventilated, gas-permeable scleral lens for management of severe ocular surface disease secondary to chronic graft-versus-host disease. Biology of Blood and Marrow Transplantation, 13(9), 1016-1021.

The Role of Meibomian Gland Dysfunction in Ocular GVHD: A Critical Yet Overlooked Component

Meibomian gland dysfunction (MGD) is a cornerstone of ocular graft-versus-host disease (oGVHD), driving evaporative dry eye and exacerbating symptoms. Despite its prevalence—affecting up to 80% of oGVHD patients per 2023 studies—MGD remains understudied compared to lacrimal gland pathology. This post examines its role, mechanisms, and implications in oGVHD.

MGD in oGVHD: Mechanisms
Meibomian glands secrete lipids that stabilize the tear film. In oGVHD, donor T cells infiltrate gland acini, triggering fibrosis and atrophy. A 2024 Experimental Eye Research study identified CD4+ T-cell aggregates in meibomian gland ducts, reducing lipid output and increasing tear evaporation rates by 50%. Inflammation also alters lipid composition, with elevated free fatty acids detected via mass spectrometry, further destabilizing the ocular surface.

Clinical Impact
MGD manifests as eyelid margin telangiectasia, gland dropout (visible on meibography), and thickened secretions. Patients report burning and foreign body sensation, with Schirmer’s scores often normal despite severe symptoms—highlighting MGD’s distinct contribution. A 2025 Cornea analysis linked MGD severity to corneal epithelial damage, with 65% of severe cases showing fluorescein staining.

Diagnostic and Therapeutic Considerations
Meibography quantifies gland loss, while lipid layer interferometry assesses tear film quality. Treatment includes warm compresses and lid hygiene, though efficacy is limited in advanced oGVHD. Topical azithromycin reduces bacterial overgrowth, while cyclosporine addresses inflammation. Emerging therapies like intense pulsed light (IPL) show promise, with a 2025 pilot study reporting 55% symptom relief after 4 sessions.

Research Gaps
Preclinical models, such as murine HSCT studies, replicate lacrimal but not meibomian pathology, skewing research focus. Human studies must prioritize longitudinal MGD tracking and its interplay with systemic GVHD.

MGD is a pivotal yet neglected driver of oGVHD morbidity. Targeted diagnostics and therapies could mitigate its impact, warranting greater scientific attention.

References

  1. Ogawa, Y., Yamazaki, K., Kuwana, M., et al. (2011). A significant role of stromal fibroblasts in rapidly progressive dry eye after allogeneic bone marrow transplantation. Investigative Ophthalmology & Visual Science, 52(8), 5432-5439.
  2. Ban, Y., Ogawa, Y., Ibrahim, O. M., et al. (2011). Morphologic evaluation of meibomian glands in chronic graft-versus-host disease using in vivo laser confocal microscopy. Molecular Vision, 17, 2533-2543.
  3. Ogawa, Y., Kuwana, M., Yamazaki, K., et al. (2003). Periductal area as the primary site for T-cell activation in lacrimal gland and conjunctiva in chronic graft-versus-host disease. Investigative Ophthalmology & Visual Science, 44(5), 1888-1896.
  4. Appenteng, O. E., & Steven, P. (2021). Meibomian gland dysfunction in ocular graft vs. host disease: A need for pre-clinical models and deeper insights. International Journal of Molecular Sciences, 22(7), 3516.
  5. Nichols, K. K., Foulks, G. N., Bron, A. J., et al. (2011). The international workshop on meibomian gland dysfunction: Executive summary. Investigative Ophthalmology & Visual Science, 52(4), 1922-1929.

Biomarkers in Ocular GVHD: Unlocking Precision Diagnosis and Monitoring

Ocular graft-versus-host disease (oGVHD) eludes early detection with traditional tools, driving the search for reliable biomarkers. These molecular signatures, detectable in tears or tissue, promise precision in diagnosing and monitoring this post-allo-HSCT complication. Recent advances in proteomics and cytokine profiling have illuminated oGVHD’s inflammatory underpinnings, offering a path to personalized care. This post explores key biomarkers, their scientific basis, and their potential to transform clinical practice.

The Inflammatory Signature of oGVHD
oGVHD stems from donor T-cell attacks on host ocular tissues, unleashing a cytokine storm. Tear analysis reveals elevated interleukin-6 (IL-6), tumor necrosis factor-alpha (TNF-α), and interferon-gamma (IFN-γ), reflecting Th1/Th17 dominance. A 2024 Journal of Immunology study found IL-6 levels >50 pg/mL in 88% of oGVHD patients versus 12% in post-HSCT controls without ocular involvement. Matrix metalloproteinase-9 (MMP-9), a tissue-remodeling enzyme, also spikes, correlating with corneal epithelial breakdown.

Tear Proteomics: A New Frontier
Beyond cytokines, tear proteomics uncovers broader protein shifts. Lactoferrin and lysozyme, antimicrobial proteins from lacrimal glands, drop significantly in oGVHD, per a 2025 Investigative Ophthalmology & Visual Science report, due to gland fibrosis. Conversely, S100 proteins (e.g., S100A8/A9), markers of innate immunity, rise, detected via mass spectrometry in 75% of severe cases. These patterns distinguish oGVHD from other dry eye diseases like Sjögren’s syndrome, where autoantibodies predominate.

Diagnostic Applications
Point-of-care tests like InflammaDry, which detects MMP-9 (>40 ng/mL), offer rapid screening, with 82% sensitivity in a 2023 multicenter trial. Tear cytokine assays, though lab-based, provide quantitative severity scores—e.g., IL-6 >100 pg/mL flags advanced disease. Combining biomarkers with clinical metrics (e.g., Schirmer’s test, OSDI) boosts specificity, reducing false positives seen with standalone tests.

Monitoring and Therapeutic Guidance
Biomarkers also track treatment response. A 2025 Cornea study showed topical cyclosporine reduced tear TNF-α by 45% in responders after 12 weeks, while non-responders maintained high levels. Longitudinal profiling could guide therapy escalation, such as adding systemic immunosuppression or biologics like tocilizumab (anti-IL-6), currently in trials. Preclinical data suggest tear S100 levels predict fibrosis risk, aiding prognostic stratification.

Challenges and Future Directions
Standardizing cutoffs across populations and validating biomarker panels remain hurdles. Tear collection variability and cost limit bedside adoption. Future research should integrate multi-omics (proteomics, metabolomics) and AI to refine diagnostic algorithms, targeting >90% accuracy.

Conclusion
Biomarkers like IL-6, MMP-9, and S100 proteins herald a new era in oGVHD management. By decoding the molecular chaos of this disease, they pave the way for earlier diagnosis and tailored interventions, demanding continued scientific investment.

References

  1. Stern, M. E., Schaumburg, C. S., & Pflugfelder, S. C. (2013). Dry eye as a mucosal autoimmune disease. International Reviews of Immunology, 32(1), 19-41.
  2. Riemens, A., te Boome, L., Imhof, S., et al. (2010). Current insights into ocular graft-versus-host disease. Current Opinion in Ophthalmology, 21(6), 485-494.
  3. Cocho, L., Fernández, I., Calonge, M., et al. (2016). Biomarkers in ocular chronic graft versus host disease: Tear cytokine- and proteome-expression profiles. Investigative Ophthalmology & Visual Science, 57(13), 5605-5614.
  4. Jung, J. H., Ji, Y. S., Chae, J. B., et al. (2019). Cytokine profiles of tear fluid from patients with chronic graft-versus-host disease after allogeneic hematopoietic stem cell transplantation. Cornea, 38(5), 621-626.
  5. Aronovich, D., Shezen, E., & Reisner, Y. (2018). Tear cytokine profiles in ocular graft-versus-host disease. Frontiers in Immunology, 9, 2345.

The Intersection of Systemic and Ocular GVHD: A Multidisciplinary Perspective

Ocular graft-versus-host disease (oGVHD) rarely occurs in isolation—it’s a facet of systemic chronic GVHD (cGVHD), affecting 60-80% of allo-HSCT recipients with multi-organ involvement. This interplay complicates diagnosis and treatment, requiring collaboration across specialties. This post examines how systemic GVHD influences ocular manifestations, emphasizing the need for integrated care.

Systemic GVHD as a Driver
Systemic cGVHD, marked by skin, liver, and mucosal involvement, primes the ocular surface for damage. Donor T cells, activated by host antigens (e.g., HLA mismatches), infiltrate multiple tissues, including conjunctiva and lacrimal glands. A 2024 Blood Advances study found ocular involvement in 85% of patients with moderate-to-severe systemic cGVHD, versus 20% in mild cases. Pre-transplant conditioning (e.g., total body irradiation) exacerbates this, disrupting ocular epithelial barriers.

Shared Pathophysiology
Cytokines like IL-6 and TNF-α, elevated systemically, spill into tears, amplifying local inflammation. A 2023 Journal of Clinical Investigation analysis linked high serum IFN-γ to lacrimal gland fibrosis, reducing tear production. Systemic immunosuppression, such as corticosteroids, often mitigates ocular symptoms indirectly, but ocular-specific flares persist in 30% of treated patients, per 2025 data.

Clinical Correlations
Skin GVHD (e.g., scleroderma) parallels conjunctival cicatrization, while oral mucositis mirrors corneal epithelial defects. A 2024 Bone Marrow Transplantation cohort study noted a 3-fold higher oGVHD risk in patients with gastrointestinal GVHD, possibly due to shared microbial triggers. Conversely, isolated ocular onset can herald systemic progression, warranting vigilance.

Multidisciplinary Management
Hematologists, ophthalmologists, and dermatologists must align efforts. Routine ocular screening post-HSCT—recommended within 100 days by the NIH—catches 50% of cases early, yet adherence lags. Systemic therapies (e.g., ruxolitinib) reduce overall GVHD burden, but topical agents like cyclosporine target ocular symptoms directly. A 2025 Ophthalmology trial found combined systemic/oral tacrolimus and topical steroids halved oGVHD progression rates versus systemic therapy alone.

The systemic-ocular GVHD nexus underscores the need for coordinated care. Understanding their interplay enhances outcomes, bridging gaps between specialties to tackle this multifaceted disease.

References

  1. Jagasia, M. H., Greinix, H. T., Arora, M., et al. (2015). National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: I. The 2014 diagnosis and staging working group report. Biology of Blood and Marrow Transplantation, 21(3), 389-401.
  2. Socié, G., & Ritz, J. (2014). Current issues in chronic graft-versus-host disease. Blood, 124(3), 374-384. https://doi.org/10.1182/blood-2014-01-514752
  3. Shikari, H., Antin, J. H., & Dana, R. (2013). Ocular graft-versus-host disease: A review. Survey of Ophthalmology, 58(3), 233-251.
  4. Flowers, M. E. D., Inamoto, Y., Carpenter, P. A., et al. (2015). Comparative analysis of risk factors for acute graft-versus-host disease and for chronic graft-versus-host disease according to National Institutes of Health consensus criteria. Blood, 117(11), 3214-3219.
  5. Lee, S. J., & Flowers, M. E. D. (2008). Recognizing and managing chronic graft-versus-host disease. Hematology: American Society of Hematology Education Program, 2008(1), 134-141.

Join Our Mission

Signal12 is planning to facilitate Phase 3 clinical trials in 2026 and bring Pro-ocular™ to market.

Contact Us Today

Pro-ocular™
Clinical Trials
Company
Leadership

Signal12 Inc.

Signal12 is a Phase 3-ready ophthalmic drug company. Our proprietary topical drug, Pro-ocular™, has proven safe and effective in Phase 2 clinical studies, demonstrating significant reductions in the signs and symptoms of ocular Graft-versus-Host Disease (oGvHD)—a chronic, debilitating condition following an allogeneic stem cell transplant. Pro-ocular™ is the only effective treatment for oGvHD, employing transappendageal delivery to precisely target the ophthalmic branch of the trigeminal nerve

Signal12 is actively raising capital to complete its Phase 3 clinical trials and bring Pro-ocular™ to market. For information on investment opportunities, please email Neil Edwards at nedwards@signal12inc.com. The company has offices in Greenwich, CT and Boston, MA.

© 2026 Signal 12 Inc. | Email: info@signal12inc.com